Shares of Veru Inc (VERU) are trading 7% higher at a price of $14.215 at the time of this writing.

Veru Inc has been trading between a 52-week high of 17.5 and a 52-week low of 4.34. The stock has a market cap of $1.14 Billion.

Veru Inc. is an oncology biopharmaceutical company with a focus on developing novel medicines for the management of prostate cancer and breast cancer. The Veru prostate cancer pipeline includes VERU-111, VERU-100, and Zuclomiphene citrate.

Why Veru Stock Got Dented Today

The Motley Fool 07-08-22

Veru drops after Culper Research releases a follow up short report

Seeking Alpha 07-08-22

MyMD, Clovis top healthcare gainers; while RAPT, Veru lead losers'' pack

Seeking Alpha 07-08-22

Today’s Hot Mover: Veru Inc. (NASDAQ:VERU), Wells Fargo & Company (NYSE:WFC)

Stock Equity 07-07-22

Why Veru Stock Trounced the Market on Thursday

The Motley Fool 07-07-22

Jefferies Analyst Predicts FDA Emergency Use Nod For Veru''s New COVID-19 Therapy In One Month

Benzinga 07-07-22

Thinking about buying stock in Allena Pharmaceuticals, Veru, Faraday Future Intelligent Electric, Adverum Biotechnologies, or Ginkgo Bioworks?

Benzinga 07-07-22

Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Thursday

InvestorPlace 07-07-22

VERU stock up as Jefferies predicts emergency nod for COVID therapy (NASDAQ:VERU)

Seeking Alpha 07-07-22

Early Moves to Watch: Nokia Oyj (NYSE:NOK), Veru Inc. (NASDAQ:VERU)

Stock Equity 07-06-22

s100cluster - 35 upvotes - source
Veru is also hiring a lot of people specifically for the Covid 19 market. See over 100 job openings on its Linkedin page [https://www.linkedin.com/jobs/search?keywords=veru&location=&geoId=&trk=public\_jobs\_jobs-search-bar\_search-submit&position=1&pageNum=0](https://www.linkedin.com/jobs/search?keywords=veru&location=&geoId=&trk=public_jobs_jobs-search-bar_search-submit&position=1&pageNum=0) Sabizabulin is an oral drug for moderate to severe cases of Covid. Sabizabulin was tested with patients who needed to be given oxygen. The drug does not need refrigeration, and Veru has also applied for EUAs in other countries.

Additional-Young-388 - 30 upvotes - source
So everyone knows. The reason approval is a slam dunk is in April it’s phase 3 was stopped early for overwhelming efficacy. In may VERU had an emergency meeting with the FDA where they were told they could submit with no further trials. In filings the FDA has approved of the drugs safety profile. And just last week the New England journal of medicine released their peer review of the phase 3 study in which the drug cut the death rate in half! This is huge! Hundreds of lives per day will be saved if not more.

gotcpip - 18 upvotes - source
You might want to work on your math. If VERU can do 10B in sales per year and the company has a PE of 15 and expenses of 1B per year you would have the following: 9B/81M shares = Earning $111 Per share - This does not account for tax $111 \* 15 = $1,665 Share price - Just an example. I am not saying VERU will ever have sales of 10B and my expense is just an estimate. Of course VERU would need to get approval first. Do your own research before investing. I am not a investment professional

Apek951 - 7 upvotes - source
Ive been making some killwr swings on veru

TianObia - 5 upvotes - source
I'm so hard rn that someone from WSB is posting about VERU, was day and swing trading it awhile ago

mrfantastic3 - 5 upvotes - source
I looked a bit on Twitter and you can find some negative commentary on the study VERU is basing its results along. I'm definitely not knowledgeable to parse this out, but thought I'd raise for discussion (caveat that its written by someone with a short position). ​ How different are these two groups? In $VERU's treatment group, approximately 17% of patients have an oxygen saturation of 89.4% or below at baseline. In the placebo group, about 37% (!!!) of patients have an oxygen saturation below 89.4% at baseline. Many of them hugely below. ​ [https://twitter.com/MidwestHedgie/status/1545045917350256646](https://twitter.com/MidwestHedgie/status/1545045917350256646)

undergraduateproject - 5 upvotes - source
It’s definitely not priced in. For one, any contract would be in the multi billion dollar range. Currently the market cap is 1.06 billion. Depending on how you value those cash flows, the price of the underlying could jump 8-15x present value on the upper range. This isn’t even taking into account potential international contracts. For example, south Korea has already notified Veru they would be interested in purchase agreements pending EUA.

Luminescent-Diatom - 5 upvotes - source
“FDA agreed that the Phase 3 COVID-19 study that was stopped by the Independent Data Monitoring Committee for overwhelming efficacy is sufficient to support the efficacy portion of a request for EUA submission and for an NDA submission. FDA agreed that the current safety data available for sabizabulin is sufficient to support the safety portion of a request for EUA submission. FDA informed the Company that additional safety data that would be collected during the use of sabizabulin under the EUA, if granted, will be sufficient to support an NDA submission, and furthermore, that no additional safety clinical studies are required.” -May 11, 2022 https://verupharma.com/news/fda-states-that-veru-should-submit-request-for-emergency-use-authorization-eua-based-on-positive-efficacy-and-safety-data-from-the-phase-3-clinical-study-of-sabizabulin-in-hospitalized-covid-19-pati/

Far-Ad-6825 - 4 upvotes - source
It's the OP's wordplay with $VERU and very which demonstrates this is a professionally researched DD.

LibrarianExternal604 - 4 upvotes - source
Think FDA come out sometime this week ,,,this is about saving ppl lives..anything involving In Covid 19..federal government will have this work fast and quick….If approve VERU likely pop around $25-$35..nice if it go $50